INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.26% | -40.24% | -50.45% | -41.91% | -28.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -76.44% | -64.73% | -52.23% | -37.45% | -23.60% |
| Total Other Non-Cash Items | 6.64% | 3.22% | 6.18% | 6.49% | -0.39% |
| Change in Net Operating Assets | -98.37% | -90.06% | 36.26% | 20.00% | 100.44% |
| Cash from Operations | -78.59% | -178.47% | -80.39% | -72.14% | -22.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -100.00% | -300.00% | -- | -- |
| Issuance of Common Stock | 4,220.65% | 3,540.13% | 3,485.68% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 486.39% | 531.03% | 1,131.25% | -- | -- |
| Foreign Exchange rate Adjustments | 51.28% | 324.00% | -173.96% | 90.91% | 105.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.34% | 8.46% | 47.02% | -25.16% | -58.98% |